TrialBMC cancer2016

HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician's choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer.

Kathy Miller et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.